Table 2.

Baseline characteristics of included nmPCa patients.

References	Country	Study design	Study period	Tumor type	Treatment	Sample size	Age	Cutoff value	Outcome	Follow-up (months)	NOS SCORE
Rajwa et al.* (24)	Multi-country	RCS	2007–2015	nmrPCa	SRP	214	69 [64–72]	730	BFS/MFS/CSS/OS	25.3 [15–28.5]	7
Rajwa et al. (25)	Multi-country	RCS	2000–2011	nmPCa	RP	6039	61 [57–66]	620	BFS	44 [31–57]	8
Wang et al. (27)	China	RCS	2014.01–2019.12	nmPCa	RP	291	66.13 ± 6.05	528.54	BFS	48 [36–62]	8

[ ], interquartile range; BFS, biochemical recurrence-free survival; CSS, cancer-specific survival; MFS, metastasis-free survival; nmPCa, non-metastatic prostate cancer; nmrPCa, non-metastatic radio-recurrent prostate cancer; OS, overall survival; RCS, retrospective cohort study; RP, radical prostatectomy; SRP, salvage radical prostatectomy. *Two studies were reported by Rajwa et al. with different populations.